Relationship between exendin-4 and neurodegenerative diseases

Chinese Pharmacological Bulletin

Volumn 26, Issue 5, 2010, Pages 566-569

  Liu, Chao ^a   Guo, Jun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

cAMP; Exendin 4; GLP 1 receptor; Neurodegenerative diseases

Indexed keywords

CYCLIC AMP; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1;

APOPTOSIS; CALCIUM HOMEOSTASIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DRUG EFFECT; EXCITOTOXICITY; NERVE CELL PLASTICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION;

EID: 77956829233     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Eng J, Kleinman W A, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom[J]. J Biol Chem,1992,267(11):7402-5.
2. VanDeKoppel S, Choe H M, Sweet B V. Managed care perspective on three new agents for type 2 diabetes[J]. J Manag Care Pharm,2008,14(4):363-80.
3. Göke R, Fehmann H C, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells[J]. J Biol Chem,1993,268(26):19650-5.
4. Al-Sabah S, Donnelly D. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors[J]. Br J Pharmacol,2003,140(2):339-46.
5. Robles G I, Singh-Franco D. A review of exenatide as adjunctive therapy in patients with type 2 diabetes[J]. Drug Des Devel Ther,2009,21(3):219-40.
6. Guang H M, Du G H. Involvment of cAMP response element binding protein in neurodegenerative disorders[J]. Chin Pharmacol Bull,2006,22(3):262-6.
7. Pedersen W A, Wan R, Zhang P, et al. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I [J]. J Neurosci,2002,22(2): 404-12.
8. Ferdaoussi M, Abdelli S, Yang J Y, et al. Exendin-4 protects β-cells from interleukin-1β induced apoptosis by interfering with the c-Jun NH2-Terminal kinase pathway[J]. Diabetes,2008,57(5):1205-15.
9. Pan J, Chen S D. C-Jun N-terminal kinase pathway and neurodegenerative disease[J]. Chin Pharmacol Bull,2008,24(8):999-1001.
10. Noma T, Yoon Y S, Nakazawa A. Overexpression of NeuroD in PC12 cells alters morphology and enhances expression of the adenylate kinase isozyme 1 gene[J]. Brain Res Mol Brain Res,1999,67(1):53-63.
11. Bertilsson G, Patrone C, Zachrisson O, et al. Peptide hormone exendin-4 stimulates sub ventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease[J]. J Neurosci Res,2008,86(2):326-38.
12. Perry T, Greig N H. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease[J]. Curr Alzheimer Res,2005,2(3):377-85.
13. Ekinci F J, Linsley M D, Shea T B. Beta-amyloid-induced calcium influx induces apoptosis in culture by oxidative stress rather than tau phosphorylation[J]. Brain Res Mol Brain Res,2000,76(2):389-95.
14. Peny T, Lahiri D K, Chen D, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells[J]. J Pharmacol Exp Ther,2002,300(3):958-66.
15. During M J, Cao L, Zuzga D S, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection[J]. Nat Med,2003,9(9):1173-9.
16. Gallagher D A, Schapira A H. Etiopathogenesis and treatment of Parkinson's disease[J]. Curr Top Med Chem,2009,9(10):860-8.
17. Harkavyi A, Abuirmeileh A, Lever R, et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease[J]. J Neuroinflammation,2008,5:19.
18. Kim S, Moon M, Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease[J]. J Endocrinol,2009,202(3):431-9.
19. Melone M A, Jori F P, Peluso G. Huntington's disease: new frontiers for molecular and cell therapy[J]. Curr Drug Targets,2005,6(1):43-56.
20. Martin B, Golden E, Carlson O D, et al. Exendin-4 Improves glycemic control, ameliorates brain and pancreatic pathologies, and Extends survival in a mouse model of huntington's disease[J]. Diabetes,2009,58(2):318-28.
21. Martin B, Golden E, Keselman A, et al. Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body[J]. Histol Histopathol,2008,23(2):237-50.
22. Li Y, Perry T, Kindy M S, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism[J]. Proc Natl Acad Sci USA,2009,106(4):1285-90.